Articles tagged with Breast Cancer
The study, involving hundreds of breast cancer patients, found that chemotherapy and hormonal treatments do not have major adverse effects on cognitive function for most older women. A small subset of patients with the APOE4 gene showed a decline in cognitive test scores after chemotherapy.
Researchers at Stevens Institute of Technology have designed a novel molecule that uses a unique mechanism to halt or destroy breast cancer tumors. The molecule, developed by Abhishek Sharma, could potentially add to the arsenal of drugs targeting estrogen receptors in breast cancer therapy.
Scientists at University of Toronto's Leslie Dan Faculty of Pharmacy have developed a combination approach using nanoparticles to improve chemotherapy response and boost anti-tumor immunity in breast cancer. The treatment resulted in a 60% cure rate and enhanced life expectancy by five-fold compared to treating with chemotherapy alone.
Aggressive breast cancer cells exploit the natural stress protector heat shock protein 70 (HSP70) to thrive and evade cell death, says a new study. The finding highlights how cancer cells manipulate tumor necrosis factor alpha (TNFα), which normally promotes self-destruction, to aid their survival.
A Mediterranean diet increased Lactobacillus abundance in mammary glands of macaque monkeys, a nonhuman primate model of women's health. This finding suggests that diet directly influences microbiome populations outside the intestinal tract and may impact breast cancer risk.
A study published in Cell Reports found that a Mediterranean diet increased mammary gland lactobacillus and reduced breast cancer risk. The researchers also plan to investigate oral interventions and bacterial-modified compounds to protect women from breast cancer.
A large observational study found that individuals with diabetes are at a higher risk of developing certain cancers, including colorectal and breast cancer. The study also showed that people with diabetes who are diagnosed with cancer have poorer survival rates compared to those without diabetes.
A recent meta-analysis of published studies found that processed meat consumption is associated with a 9% higher breast cancer risk. However, no significant association was observed between red (unprocessed) meat intake and breast cancer risk. The study suggests cutting down processed meat may be beneficial for preventing breast cancer.
A large observational study found that adults with type 2 diabetes are at greater risk of dying from cancer, particularly obesity-related cancers. Non-obesity related cancers also pose a significant threat to individuals with type 2 diabetes.
Patients with respiratory tract infections receiving antibiotics had significantly shorter telemedicine encounters than those not receiving antibiotics. Researchers found that antibiotic prescriptions were about 33 seconds shorter, while non-antibiotic prescriptions resulted in longer encounters of approximately 1 minute and 12 seconds...
A new study from George Washington University Cancer Center found that nanoparticle-encapsulated doxorubicin is promising in treating triple-negative breast cancer. The smallest nanoparticles with slowest release of medication showed increased cell kill in resistant cancer cells, offering potential strategies to overcome drug resistance.
Researchers create 3D models of breast cancer tumors using stromal cells, which play a major role in cancer growth and progression. The study aims to introduce stromal cells as new therapeutic targets, offering potential treatments for triple-negative breast cancer.
Researchers at UCI will develop a new class of cancer-killing immunotherapeutics targeting abnormal glycans, which are nearly universal in cancer but limited in normal tissue. The goal is to broaden the types of cancers sensitive to immunotherapy and treat highly diverse types of cancer.
Researchers are investigating how a gene that regulates estrogen and neurotransmitter levels could be tied to cognitive decline in patients undergoing chemotherapy. The study aims to understand the underlying factors of treatment-related cognitive dysfunction, also known as chemo brain.
A study by Medical University of South Carolina found that breast cancer patients who received a second opinion at an NCI-designated center experienced a significant change in diagnosis, with 43% of cases altered. The review by a multidisciplinary tumor board led to the identification of additional cancers in 16 patients and changes in...
Researchers develop new theory to explain how tumors spread, revealing competition between forces that shape their growth. The 'active wetting' model suggests tumors behave like active drops, with cells creating forces and moving on their own.
A study published in the American Cancer Society journal found that black women and women living in poverty are less likely to report barriers to breast cancer screening due to medical distrust and social norms. Patient navigators can reduce disparities, but require training to address diverse needs.
Researchers have identified a link between inflammation and cancer growth in HER2-negative breast cancers, revealing anakinra as a potential treatment target. Anakinra, an existing anti-inflammatory drug, reduces gene expression of IL1b and other cytokines, improving symptoms and quality of life for some patients.
A new study reveals that black women are more likely to skip hormone therapy treatments for breast cancer, with barriers including cost, side effects, and difficulty adhering to treatment plans. The study highlights the need for culturally competent behavioral interventions to improve outcomes for all women with breast cancer.
Purdue University researchers have simulated how over 20 different breast tissue ratios respond to heat given off by MRIs at higher field strengths. The simulations showed that a fivefold increase in SAR could still stay within FDA limits for most breast tissue ratios, enabling the use of 7 tesla technology for safer cancer detection.
A new study by George Mason University researchers found links between chemicals used in personal care products and changes in reproductive hormones. The study, which analyzed 509 urine samples from 143 women aged 18-44, suggests that even low-level exposure to mixtures of chemicals may affect reproductive hormone levels.
A Danish-Norwegian study found that breast cancer mortality is declining due to better treatment, not screening. The study challenges the effectiveness of breast cancer screening programs, suggesting alternative methods like palpation.
Researchers have analyzed nearly 4,000 mutations in the BRCA1 gene, shedding light on its role in breast and ovarian cancer. The findings provide immediate benefits to patients with previously inconclusive genetic test results, enabling clinicians to better interpret variant of uncertain significance.
A study at the University of Chicago Medical Center and University of Washington found that twice-a-year MRI scans detected more small early stage breast cancers than annual mammograms. The research suggests that intensive surveillance can be crucial for improving outcomes in young women with high-risk genetic mutations.
A new study from the University of Missouri School of Medicine reveals that more than half of women with breast cancer are now receiving their diagnosis over the phone. The researchers found a significant shift in diagnosis delivery method since 2007, when approximately 25 percent of patients learned about their diagnosis via phone.
Researchers found that EVL protein helps contain cancer cells within the original tumor site by regulating actin cytoskeleton, which may lead to combination treatments for patients with ER-positive tumors.
Researchers at VCU Massey Cancer Center identified the enzyme cyclophilin A as a potential target for treating breast cancer. By inhibiting this enzyme, they were able to slow or halt the growth of breast cancer cells. The discovery builds on previous work and holds promise for rapid development of novel therapies.
A new imaging method targets cancer-associated fibroblasts to diagnose widespread tumors like breast, colon, and pancreas cancer with better accuracy and less inconvenience. The tracer shows high tumor uptake and image contrast, making it a promising strategy for detection and treatment of malignant tumors.
Researchers developed a new way to identify molecular markers of breast cancer tumors using machine learning. This technology can rapidly sort images of breast tumors to determine prognosis and treatment options, potentially leading to faster and more cost-effective treatments for millions of women.
A new study published in eLife suggests that the overall burden of changes in a tumor's genome can predict patient outcomes across various cancer types. Researchers found that the percentage of altered genes in a tumor, known as CNA burden, is associated with mortality and disease-free survival in multiple cancers.
A large genomic analysis has linked certain DNA mutations to a high risk of relapse in estrogen receptor positive breast cancer, while other mutations were associated with better outcomes. The study identified three genes - DDR1, PIK3R1 and NF1 - with relatively uncommon mutations that were associated with cancer recurrence and spreading.
Researchers at Mayo Clinic have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast cancer. The study found that cyclocreatine effectively targets mitochondrial creatine kinase 1 enzyme and reduces cancer growth without toxicity.
A team at the Salk Institute has identified a genetic master switch, Sox10, that controls the growth and invasion of aggressive triple-negative breast cancers. This discovery may lead to new avenues for diagnosing and treating intractable cancers by targeting specific genes.
University of Toronto researchers have identified protein NUAK2, associated with poor disease prognosis in bladder cancer. Blocking NUAK2 slows down cancer cell growth and raises hopes for treating patients.
For frail nursing home residents with breast cancer, surgery often cures the cancer but worsens quality of life and daily activities. Researchers recommend individualized care with hormonal therapy or symptom management instead.
Researchers at Hong Kong Baptist University have developed a metal compound that inhibits the enzyme lysine-specific demethylase 5A (KDM5A) in TNBC tumours with less toxicity in mice. This discovery holds great promise for the development of targeted drugs for TNBC therapy, offering a new approach to treating this difficult form of bre...
Researchers identified six protein kinases that predict the evolution of triple negative breast cancer, allowing for new pharmacological targets and potential treatment combinations. The study's findings indicate a high cure rate (95%) for patients with no activated proteins, but increased relapse risk if one or more are active.
A study published in the Journal of the American Geriatrics Society found that short-term decline in physical function was common among older adults treated with chemotherapy for breast cancer. However, about half of patients were resilient and able to recover their ability to function within 12 months.
Researchers found that inflammatory response triggered by primary breast cancer prevents tumor cells from growing in distant organs. Inhibitors of interleukin-1β, such as canakinumab, are being tested in clinical trials for potential benefits in preventing metastatic growth.
Researchers discovered a previously unseen 'ecosystem' in advanced breast cancer, where primary tumors emit signals to halt secondary tumor growth. The study found that activating the immune response can freeze secondary cancers, offering new hope for living with advanced breast cancer.
A study defines mechanisms behind focused-ultrasound-assisted treatment of brain tumors, improving drug delivery across the blood-brain barrier and into abnormal tumor tissues. The approach enhances permeability of endothelial cells lining tumor blood vessels, increasing cellular uptake of anti-cancer drugs.
A new web-based calculator, CTS5, can accurately predict the long-term risk of breast cancer returning in other areas of the body. The tool helps clinicians decide whether to continue or stop hormone therapy, improving patient quality of life and reducing unnecessary treatment.
A study led by Johns Hopkins Bloomberg School of Public Health researchers found that breast cancer survivors, particularly those with lymphedema, incur significant out-of-pocket costs. The average annual cost for those with lymphedema was $2,306 excluding productivity costs and $3,325 including productivity costs.
A new study from Barcelona Institute for Global Health found that women living closer to urban green spaces had a lower risk of breast cancer. The study, which analysed data from over 3,600 women in Spain, concluded that proximity to parks or gardens was associated with reduced breast cancer risk.
Researchers identified genetic mutations associated with increased risk of breast cancer in Nigerian women. The study found that nearly half of patients were diagnosed with triple-negative breast cancer, an aggressive subtype with poor prognosis.
The EMBRACA trial shows that talazoparib provides a significant clinical benefit to patients with metastatic breast cancer and BRCA mutations. The study found that talazoparib improved progression-free survival, quality-of-life measures, and overall response rates compared to chemotherapy.
A recent study found that only 8% of disabled or older women who qualified for Medicare received BRCA1 and BRCA2 testing between 2000 and 2014. Women with these mutations are at higher risk for developing second breast cancer and ovarian cancer, making timely testing crucial for informed decision-making.
Research reveals key physical properties of giant cancer cells, including stiffness and ability to move further than standard cancer cells. This understanding may lead to the development of targeted treatments.
Researchers have identified a potential new treatment for aggressive breast cancer by targeting the communication channel between non-cancerous cells and tumour cells. The study, published in Nature Communications, shows that disrupting this connection can slow tumour growth, increase sensitivity to chemotherapy and improve survival.
A small clinical benefit was observed in reduced risk of dying from breast cancer in women with ductal carcinoma in situ (DCIS) treated with radiation plus lumpectomy. The absolute risk reduction was 0.27 percent, indicating that 370 women would need to be treated to save one life.
Researchers discovered a previously unrecognized mechanism by which arsenic trioxide and all-trans retinoic acid work together to destroy Pin1, a unique enzyme that activates over 40 cancer-driving proteins. This finding suggests novel strategies to treat common cancers, including triple-negative breast cancer.
Researchers from NTU and Harvard found that adding nano-sized cellulose fibers to food reduced fat absorption by up to half in laboratory and animal experiments. The discovery could aid in the global battle against obesity by reducing fat absorption, a strategy reinforced by existing knowledge on high-fibre diets.
Researchers at Salk Institute identify genetic features of human basal-like breast cancers that share similarities with embryonic mammary stem cells, which may be targeted therapeutically. The study provides insights into how cancer cells gain plasticity and become resistant to therapies.
A new study has identified specific genes, including BARD1, BRCA1, BRCA2, PALB2, and RAD51D, that are associated with an increased risk for triple-negative breast cancer. The study suggests potential revisions to guidelines for genetic testing and may lead to better prevention strategies.
Scientists at Huntsman Cancer Institute have generated a comprehensive molecular map of genes that control breast tissue formation, providing new insights into the development of breast cancer. The study identifies hundreds of potentially critical genes for further research as regulators of normal and cancerous development.
Researchers have discovered that PLK1 acts as a tumor suppressor in some breast tumors, halting development and changing prognosis. This finding was made by researchers from CNIO and DKFZ.
Researchers used a PET tracer to identify differences in ER expression across metastases and surrounding normal tissue in breast cancer patients. The study found that approximately 50% of patients had one or more estrogen-receptor negative lesions, highlighting the heterogeneity of ER expression.
A Mayo Clinic research team has identified specific genes associated with an increased risk for developing triple-negative breast cancer. Alternations in BARD1, BRCA1, BRCA2, PALB2 and RAD51D genes were linked to a high risk for this subtype of breast cancer, while mutations in BRIP1 and RAD51C genes showed a moderate risk.
A recent study found that 8.3% of trastuzumab-treated patients developed heart failure, highlighting the need for cardiac monitoring in high-risk breast cancer patients. The study also showed a consistent increase in heart failure risk with age, emphasizing the importance of prioritizing cardiac monitoring for younger patients.
Experimental studies reveal a strong interplay between liganded and non-liganded transcriptional activations of ERs. Natural estrogens can restore DNA surveillance in tumor cells via harmonized transactivation of AF1 and AF2 domains.